You are here

  • Home
  • Archive
  • Volume 107, Issue 2
  • Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people

Article Text

Article menu
Download PDFPDF
Correspondence
Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people
  1. Julia Hippisley-Cox1,
  2. Pui San Tan1,
  3. Carol Coupland2
  1. 1 Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  2. 2 Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, UK
  1. Correspondence to Dr Julia Hippisley-Cox, Primary Care Health Sciences, Oxford University, Oxford OX1 2JD, UK; Julia.Hippisley-Cox{at}phc.ox.ac.uk

https://doi.org/10.1136/heartjnl-2020-318312

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The Authors’ reply

    We thank interested readers and their interesting views and opinions on our recently published study ‘Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people’.1 Please find our responses to views and comments as follows.

    In this study, the most recent smoking records available from general practices were used prior to cohort entry. Smoking status was recorded for 96% of patients included in the study, although recent changes in smoking status might not have been recorded. At the point of analyses of the study, negative test results were not yet available from Public Health England (PHE). However, we agree that it will be useful to compare clinical and demographic characteristics between COVID-19 positive and negative test …

    View Full Text

    Footnotes

    • Twitter @juliahcox

    • Contributors All authors contributed to this reply to reviewers.

    • Funding This study was funded by John Fell Oxford University Press Research Fund, Wellcome Trust (221514/Z/20/Z), Oxford Wellcome Institutional Strategic Support Fund (204826/Z/16/Z) and Cancer Research UK (C5255/A18085).

    • Competing interests JH-C reports grants from the National Institute for Health Research Biomedical Research Centre, Oxford, grants from John Fell Oxford University Press Research Fund, grants from Cancer Research UK (CRUK) grant number C5255/A18085, through the Cancer Research UK Oxford Centre, and grants from the Oxford Wellcome Institutional Strategic Support Fund (204826/Z/16/Z), during the conduct of the study; personal fees and other from ClinRisk (until 2019), outside the submitted work; and is an unpaid director of QResearch, a not-for-profit organisation which is a partnership between the University of Oxford and EMIS Health, which supply the QResearch database used for this work. PST reports consulting with AstraZeneca and Duke-NUS, outside the submitted work. CC has nothing to disclose.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Patient consent for publication Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    • Correspondence
      Risk of COVID-19 and smoking
      Ivan Berlin
      Heart 2020; 107 170-170 Published Online First: 04 Nov 2020. doi: 10.1136/heartjnl-2020-318311